

Prognostic and predictive biomarkers in oesophagogastric cancer

Citation for published version (APA):

Hewitt, L. C. (2019). *Prognostic and predictive biomarkers in oesophagogastric cancer*. [Doctoral Thesis, Maastricht University]. Optima, Rotterdam. <https://doi.org/10.26481/dis.20191128lh>

Document status and date:

Published: 01/01/2019

DOI:

[10.26481/dis.20191128lh](https://doi.org/10.26481/dis.20191128lh)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Propositions

Belonging to the thesis entitled

Prognostic and predictive biomarkers in oesophagogastric cancer

1. The frequency of tumour based molecular alterations including *KRAS* mutation, *KRAS* amplification, Epstein-Barr virus and microsatellite instability is low in oesophagogastric cancer (this thesis)
2. Treatment de-escalation strategies should be considered for gastric cancer patients with a very high number of tumour infiltrating lymphocytes as these patients have no survival benefit from adjuvant chemotherapy (this thesis).
3. Heterogeneity of the tumour stroma content between biopsy pieces predicts benefit from cytotoxic chemotherapy in oesophageal cancer patients from the Oe02 trial and may represent a clinically useful biomarker for patient treatment stratification (this thesis).
4. Successful translation of biomarkers to the clinic requires completion of biomarker development roadmaps agreed by the scientific community including prospective analysis of retrospectively collected material from phase III clinical trials (this thesis).
5. Clinical application of predictive biomarkers has the potential to reduce healthcare costs and at the same time improve survival and quality of life for oesophagogastric cancer patients, as only those who benefit from chemotherapy would be treated (valorisation, this thesis).
6. Unbiased science requires publication of negative results as well as positive results to prevent wasted efforts and facilitate progress in the field.
7. Complex scientific problems are best solved by collaboration with experts from a variety of cross-disciplinary areas with different expertise.
8. "It's far more important to know what person the disease has than what disease the person has" – **Hippocrates**
9. If you never try, you'll never know